drugset / Trial / NCT03315780

A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes

NCT03315780

Phase 4 Completed 12 enrolled Eli Lilly and Company
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to evaluate the glucodynamic effects of dulaglutide in Japanese participants with type 2 diabetes mellitus.

Timeline

Start
2017-10-28
Primary completion
2018-02-28
Completion
2018-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 0.75 mg Subcutaneous